I can’t really talk much more about this program at this stage...

I can’t really talk much more about this program at this stage beyond making our shareholders aware of it and may be add that it is well advanced. You can expect to hear more specific over the months ahead.

The whole m6A RNA regulation area is hot and in my opinion it is going to get a lot hotter in the coming months and years. We are one of the few companies in the world with an active research program in this area and we have the skills, background and collaborators to build on this activity. For a relatively small amount of money ($800K) we think we can take advantage of all this and generate serious extra value for our shareholders without being a distraction from our focus on Zantrene.

If you want to have an idea of what this program could mean take a look at the deals Ipsen did with Accent Therapeutics [1] or Excelixis did with Storm Therapeutics [2].

1. https://www.accenttx.com/press-releases/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3/

2. https://www.businesswire.com/news/home/20211014005548/en/Exelixis-and-STORM-Therapeutics-Enter-into-Exclusive-Collaboration-and-License-Agreement-to-Discover-and-Develop-Inhibitors-of-Novel-RNA-Modifying-Enzymes